Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2020

01-04-2020 | Breast Cancer | Letter to the Editor

CYP24A1 polymorphisms and breast cancer risk

Authors: Beuy Joob, Viroj Wiwanitkit

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Login to get access

Excerpt

Dear Editor, we read the publication on “The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer (BC) risk” with great interest [1]. Cao et al. noted that “Significant interactions of weight change with CYP24A1 polymorphisms suggest CYP24A1 as a potential link between weight change and BC risk [1].” Indeed, there are several factors that are associated with BC risk. Regarding the effect of CYP24A1 polymorphisms, single mutations were studied by Cao et al. The pathogenesis of studied CYP24A1 polymorphisms is molecular change due to mutation. Based on the standard molecular calculation technique, as mentioned in previous publications [2], the molecular weight changes in C/T and A/G variants are equal to + 15 (from 111.1 to 126.1) and + 16 ( from 135.1 to 151.1) g/Mol, respectively. Nevertheless, there are also other possible genetic polymorphisms that are related to BC risk. The examples are ACVB1 and AGER polymorphisms [3, 4]. The effects of other additional confounding factors should be assessed in future studies. …
Literature
2.
go back to reference Joob S, Guran M (2019) PRDM1 rs1010273 polymorphism and survival of patients with hepatitis B virus-related hepatocellular carcinoma. Adv Lab Med Int 9:31–32 Joob S, Guran M (2019) PRDM1 rs1010273 polymorphism and survival of patients with hepatitis B virus-related hepatocellular carcinoma. Adv Lab Med Int 9:31–32
3.
go back to reference Liu H, Wei Z, Shi K, Zhang Y (2019) Association between ABCB1 G2677T/A Polymorphism and Breast Cancer Risk: A Meta-Analysis. Crit Rev Eukaryot Gene Expr 29(3):243–249CrossRef Liu H, Wei Z, Shi K, Zhang Y (2019) Association between ABCB1 G2677T/A Polymorphism and Breast Cancer Risk: A Meta-Analysis. Crit Rev Eukaryot Gene Expr 29(3):243–249CrossRef
4.
go back to reference Ghafouri-Fard S, Noroozi R, Musavi M, Taheri M (2019) Association analysis between genomic variants within advanced glycation end product specific receptor (AGER) gene and risk of breast cancer in Iranian women. Heliyon 5(10):e02542CrossRef Ghafouri-Fard S, Noroozi R, Musavi M, Taheri M (2019) Association analysis between genomic variants within advanced glycation end product specific receptor (AGER) gene and risk of breast cancer in Iranian women. Heliyon 5(10):e02542CrossRef
Metadata
Title
CYP24A1 polymorphisms and breast cancer risk
Authors
Beuy Joob
Viroj Wiwanitkit
Publication date
01-04-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05553-1

Other articles of this Issue 2/2020

Breast Cancer Research and Treatment 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine